Trans Chromosomics Inc.
PrivateLast Round
Grant
Jun 30, 2025
Total Funding Raised
$872,888
Company Overview
Trans Chromosomics Inc. is a biotechnology company that provides a drug discovery platform utilizing chromosome engineering technology, including the development of human antibody-producing animals and models for evaluating drug efficacy and toxicity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Trans Chromosomics Inc. Comparables
Compare Trans Chromosomics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Harbour BioMed | 78% | |
| Cyagen Biosciences | 78% | |
| Biocytogen | 77% |
Trans Chromosomics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 30, 2025 | ||||
| Grant | Sep 25, 2024 | ||||
| Grant | Jul 22, 2023 | ||||
| VC Round | Jun 27, 2019 | ||||
| VC Round | Jul 27, 2018 | ||||
VC Round | Jan 25, 2017 |
Trans Chromosomics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TNP Threads of Light | VC Round |
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Tottori Capital | VC Round |
| North Carolina Department of Commerce | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2025
$75K grant from North Carolina Department of Commerce.
- Oct 29, 2024
Monthly visitors increased 33% MoM.
Trans Chromosomics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Trans Chromosomics Inc.'s valuation, stock price, and market status.
Is Trans Chromosomics Inc. a public or private company?
Trans Chromosomics Inc. is a private company.
What is the current stock price of Trans Chromosomics Inc.?
Trans Chromosomics Inc. is a private company, so its shares have no public market price. Caplight tracks Trans Chromosomics Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Trans Chromosomics Inc. worth (valuation)?
Valuation information for Trans Chromosomics Inc. is not publicly available.
Can I buy Trans Chromosomics Inc. stock?
Trans Chromosomics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Trans Chromosomics Inc.'s last funding round?
Trans Chromosomics Inc.'s most recent funding round was Grant on June 30, 2025.
Who are the main investors in Trans Chromosomics Inc.?
Key investors in Trans Chromosomics Inc. include NIH RADx, National Institute of Diabetes and Digestive and Kidney Diseases, Tottori Capital, North Carolina Department of Commerce.
Will Trans Chromosomics Inc. IPO soon?
No public IPO plans have been announced for Trans Chromosomics Inc..
How can I track Trans Chromosomics Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Trans Chromosomics Inc.'s shares on secondary markets.